Gainers
-
Kadmon Holdings Inc (NYSE: KDMN) shares
are up 14 percent after announcing positive topline results from a Phase 2 study of KDO25.
-
Vipshop Holdings Ltd – ADR (NYSE: VIPS)
shares are up 10 percent after reporting a fourth quarter earnings and sales beat. Adjusted earnings came in at 22 cents per
share, beating estimates by 2 cents. Sales came in $20 million higher than estimates at $3.7 billion.
-
Servicesource International Inc (NASDAQ: SREV) shares are up 9 percent following a top and bottom line beat in the
fourth quarter. The company also announced the signing of multi-year contract extensions with two long-standing technology
clients.
-
Chegg Inc (NYSE: CHGG) shares are up 4
percent after reporting a fourth quarter earnings and sales beat and raising FY18 guidance. Fourth quarter adjusted EPS came in
at 17 cents per share, beating estimates by 4 cents. Sales came in at $74 million, topping estimates by $3 million. The company
sees FY18 sales in the range of $295 million-$300 million.
Losers
-
Helios and Matheson Analytics Inc (NASDAQ: HMNY) shares are down 16 percent after reporting an offering of common stock.
The size was not disclosed.
-
Affimed NV (NASDAQ: AFMD) shares are
down 12 percent following the announcement of a common stock offering. The size was not disclosed.
-
Pacific Biosciences of California (NASDAQ: PACB) shares are down 9 percent following the announcement of a common stock
offering. The size was not disclosed.
-
Dare Bioscience Inc (NASDAQ: DARE)
shares are down 8 percent. Shares spiked 50 percent in the regular session, following the announcement that the company entered
a partnership deal with Strategic Science & Technologies to develop topical Sildenafil.
-
Molina Healthcare, Inc. (NYSE: MOH) shares
are down 6 percent after reporting its fourth quarter earnings report. Fourth quarter GAAP EPS came in at $(4.59). Premium
sales came in at $4.689 billion, up from $4.19 billion in the same quarter of last year. The company sees FY18 adjusted EPS in
the range of $3.23-$3.73 against a consensus $3.49 estimate.
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.